BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 31337655)

  • 21. COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells.
    Prima V; Kaliberova LN; Kaliberov S; Curiel DT; Kusmartsev S
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1117-1122. PubMed ID: 28096371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti-PD-L1 Therapy via IRF8 Expression.
    Patel A; Oba T; Kajihara R; Yokoi T; Abrams SI; Ito F
    J Immunol; 2021 Sep; 207(5):1298-1309. PubMed ID: 34362833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells.
    Xie Z; Ago Y; Okada N; Tachibana M
    J Pharmacol Sci; 2018 Aug; 137(4):359-365. PubMed ID: 30177294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.
    Lee-Chang C; Rashidi A; Miska J; Zhang P; Pituch KC; Hou D; Xiao T; Fischietti M; Kang SJ; Appin CL; Horbinski C; Platanias LC; Lopez-Rosas A; Han Y; Balyasnikova IV; Lesniak MS
    Cancer Immunol Res; 2019 Dec; 7(12):1928-1943. PubMed ID: 31530559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Granulocytic myeloid-derived suppressor cells inhibit T follicular helper cells during experimental Schistosoma japonicum infection.
    Zhang Y; Wu Y; Liu H; Gong W; Hu Y; Shen Y; Cao J
    Parasit Vectors; 2021 Sep; 14(1):497. PubMed ID: 34565440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells.
    Singh L; Muise ES; Bhattacharya A; Grein J; Javaid S; Stivers P; Zhang J; Qu Y; Joyce-Shaikh B; Loboda A; Zhang C; Meehl M; Chiang DY; Ranganath SH; Rosenzweig M; Brandish PE
    Mol Cancer Res; 2021 Apr; 19(4):702-716. PubMed ID: 33372059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer.
    Wang G; He L; Wang S; Zhang M; Li Y; Liu Q; Sun N; Zhang X; Liu Y; Zhang J; Tai J; Ni X
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32459310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using
    Liechtenstein T; Perez-Janices N; Blanco-Luquin I; Goyvaerts C; Schwarze J; Dufait I; Lanna A; Ridder M; Guerrero-Setas D; Breckpot K; Escors D
    Oncoimmunology; 2014; 3(7):e945378. PubMed ID: 25954597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic and local immunosuppression in patients with high-grade meningiomas.
    Li YD; Veliceasa D; Lamano JB; Lamano JB; Kaur G; Biyashev D; Horbinski CM; Kruser TJ; Bloch O
    Cancer Immunol Immunother; 2019 Jun; 68(6):999-1009. PubMed ID: 31030234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
    Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
    J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells.
    Xiao W; Klement JD; Lu C; Ibrahim ML; Liu K
    J Immunol; 2018 Jul; 201(1):264-277. PubMed ID: 29752314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma.
    Weber R; Riester Z; Hüser L; Sticht C; Siebenmorgen A; Groth C; Hu X; Altevogt P; Utikal JS; Umansky V
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation.
    Li Y; Acharya G; Elahy M; Xin H; Khachigian LM
    Cancer Lett; 2019 Sep; 459():268-276. PubMed ID: 31128215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloid-Derived Suppressor Cells Are a Major Source of Wnt5A in the Melanoma Microenvironment and Depend on Wnt5A for Full Suppressive Activity.
    Douglass SM; Fane ME; Sanseviero E; Ecker BL; Kugel CH; Behera R; Kumar V; Tcyganov EN; Yin X; Liu Q; Chhabra Y; Alicea GM; Kuruvilla R; Gabrilovich DI; Weeraratna AT
    Cancer Res; 2021 Feb; 81(3):658-670. PubMed ID: 33262126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
    Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
    J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.
    Alissafi T; Hatzioannou A; Mintzas K; Barouni RM; Banos A; Sormendi S; Polyzos A; Xilouri M; Wielockx B; Gogas H; Verginis P
    J Clin Invest; 2018 Aug; 128(9):3840-3852. PubMed ID: 29920188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.